Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexeo Therapeutics, Inc. - Common Stock (NQ:LXEO)

3.060 -0.410 (-11.82%)
Streaming Delayed Price Updated: 12:38 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexeo Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Pharma Frenzy: Volatility Ignites Biotech Sector
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value. 
Via MarketBeat
Exposures Product Safety
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss. 
Via Stocktwits
What's going on in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Monday's session.
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
Via Benzinga
Exposures Fossil Fuels
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
Via Benzinga
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease. 
Via Investor's Business Daily
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
From Lexeo Therapeutics
Via GlobeNewswire
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
Via Benzinga
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor... 
From Lexeo Therapeutics
Via GlobeNewswire
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
Via Benzinga
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor... 
From Lexeo Therapeutics
Via GlobeNewswire
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
From Lexeo Therapeutics
Via GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
Via Benzinga
Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Fastenal Company (NASDAQ: FAST) rose during Thursday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From LEXEO Therapeutics
Via GlobeNewswire
Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 40 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.